Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Items 401–500 of 529
Elezz, A. M. A., khalefa, K. A., Gadelmawla, A. F., Khattab, Y. A., & Zeid, M. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01873-0 · Cited by 8
Tsai, W.-W., Lu, K.-H., Wu, J., Chuang, M., Chen, J., Lai, C.-C., Hung, K. C., & Hsieh, M. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251372747 · Cited by 9
“28 Consequently, eight studies 11–14 , 28–31”
Schechter, M., Fishkin, A., Mosenzon, O., Sehtman-Shachar, D. R., Cukierman‐Yaffe, T., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02962-8 · Cited by 10
“A 2013 single-blind proof-of-concept trial of 45 people with moderate Parkinson's disease found that 12-month exenatide therapy compared with non-use was associated with improvements in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) [24].”
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 8
“Exenatide, using a subcutaneous dose of 2 mg, identical to the licensed dose for T2DM, has demonstrated its ability to cross the BBB and be detectable in cerebrospinal fluid at concentrations similar to those associated with beneficial outcomes in preclinical models [5,93,94,99].”
Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review
Lee, S., Yin, L., Teopiz, K. M., Wong, S., Le, G. H., Xiao, N., Stahl, S. M., Valentino, K., Ho, R., Zhang, M. C., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251396304 · Cited by 10
“24 After ).”
Ashraf, T., Abunada, O., Kumar, A., Ahmed, S., Siddiqui, M. B. A., Memon, U. F., Dev, S., Meghjiani, A., Turesh, M., Khatri, G., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002908 · Cited by 6
Rimal, N., Khanal, S., Bohara, G., & Choi, D. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110643 · Cited by 7
Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes
Maestre, G. E. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0216-y · Cited by 5
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 6
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 6
Ai, N., Wang, D., Qu, S., Vong, C. T., Yuan, M., Su, H., Ge, W., & Chong, C. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.08.021 · Cited by 6
Shirani, A., & Stüve, O. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2587277 · Cited by 7
Stefanou, M., Panagiotopoulos, E., Tentolouris, A., Theodorou, A., Papagiannopoulou, G., Athanasaki, A., Tsalouchidou, P., Peppa, Μ., Lambadiari, V., Konitsiotis, S., et al. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251408269 · Cited by 8
Ciocca, M., & Pizzamiglio, C. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330122444 · Cited by 6
“GLP-1 receptors have been identified in different brain areas, and in vitro and in vivo studies have suggested that exenatide may have neuro-protective and neurorestorative effects [49].”
BackgroundInfluentialNovel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms
Ullah, I., Wang, X., & Li, H. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07278-7 · Cited by 4
“In the PC12 cells, exenatide stimulated neurite outgrowth via the MAPK and phosphatidylinositol 3 kinase (PI3K) signaling pathways [215].”
Rani, N., Kaushik, A., Kardam, S., Kag, S., Raj, V. S., Ambasta, R. K., & Kumar, P. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.029 · Cited by 5
Glial GLP1R: A novel neuroprotector?
Schonhoff, A. M., & Harms, A. S. (2018) · Movement Disorders · doi:10.1002/mds.27547 · Cited by 5
“GLP1R agonists are approved for the treatment of type 2 diabetes, and clinical trials have begun in neurodegenerative diseases.(4) Although this article identifies microglial-mediated astrocyte conversion as a primary target for GLP1R agonists, it will be critical to define how A1 astrocytes directly contribute to neu…”
BackgroundYao, K., Wang, J., Ma, B., He, L., Zhao, T., Zou, X., Weng, Z., & Yao, R. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1093154 · Cited by 6
Park, S.-H., & Kim, D. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.160078 · Cited by 4
“In phase 2 clinical trials, the safety and efficacy of long-term exendin-4 treatment were evaluated (Aviles-Olmos et al., 2013).”
BackgroundNonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
Nogueira, L., Mazetto, R. A. S. V., Defante, M. L. R., Antunes, V., Gonçalves, O. R., Corso, A. M. S., Coletta, M. V. D., Boone, D. L., Filho, W. S. M., Borges, V., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1806824 · Cited by 5
“All 4 studies 7,8,16,17 analyzed part I of the MDS-UPDRS at 6 months and included 510 patients.”
InfluentialCosta, G. V. L., Cavalcante, L. F. F., Battistuta, S. M., Makabe, P. F., Bueno, I. S. F., Yuamoto, B., Vilela, F., Meloni, L. G. G., de Faria, D. D., Anghinah, R., et al. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200548 · Cited by 3
M14 substitutions in exanatide modulate alpha‐synuclein aggregation
Panuganti, V., Manchanda, K., Bharatam, P. V., & Roy, I. (2025) · FEBS Journal · doi:10.1111/febs.70321 · Cited by 4
“Reports in human patients have also shown promising results [24,25].”
Sharallah, O. A., Malakar, V. K., Salama, A. E., Elmaaz, S. M., Daba, S. A., & Poddar, N. K. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01702-0 · Cited by 4
Recent Developments in the Drug Treatment of Parkinson’s Disease
Leiter, S., Mahlknecht, P., & Poewe, W. H. (2026) · Drugs · doi:10.1007/s40265-026-02327-9 · Cited by 4
“To date 6 randomised placebo-controlled trials have investigated the efficacy and safety of GLP1 agonists in early to moderately advanced PD (Table 4; [183–188]).”
Bhatt, T., Patel, B. M., & Patel, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819838-4.00028-6 · Cited by 3
Doggrell, S. A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2459409 · Cited by 3
“‘On-medication’ scores for MDS-UPDRS part 3 also favored exenatide at 12 and 14 months, with the differences being 6.3 and 9.8 points, respectively [11].”
InfluentialRai, P., & Kumar, R. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114460 · Cited by 3
O EFEITO DOS ANÁLOGOS DE GLP1 NA MASLD: MECANISMOS, EVIDÊNCIAS E PERSPECTIVAS
Prudente, L. L., de Oliveira, G. A. M., & Cardoso, M. A. P. (2025) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/t9z40s73 · Cited by 3
Of mice and men: incretin actions in the central nervous system
Farr, O. M., Pilitsi, E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.013 · Cited by 3
Syvänen, V., Koıstınaho, J., & Lehtonen, Š. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322988 · Cited by 4
“Furthermore, therapeutic effects of exendin-4 have also been evaluated in randomized controlled trials with PD patients [121,122].”
BackgroundNeuroprotective strategies in Parkinson’s disease: A long road ahead
Garg, D., & Desai, S. (2021) · Annals of Movement Disorders · doi:10.4103/aomd.aomd_38_21 · Cited by 4
Drug repurposing for neurodegenerative diseases
Shukla, H., John, D., Banerjee, S., & Tiwari, A. K. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.035 · Cited by 3
Modern Pharmacological Treatment of Parkinson's Disease : Reviving Known Drugs and New Perspectives
Lastovetskyi, I., Cytlau, B., Marczyk, Ł., Zdrojewska, K., Łach, A., Krupa, J. K., Lorkowska-Zawicka, B., & Bujak-Giżycka, B. (2024) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/twysubd6pp · Cited by 6
Vogrinc, D., Redenšek, S., Blagus, T., Trošt, M., Kramberger, M. G., Emeršič, A., Čučnik, S., Goričar, K., & Dolžan, V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39157 · Cited by 4
“Treatment with exendin-4 led to a mild improvement in motor symptoms measured by the MDS-UPDRS III of PD patients [11], while liraglutide maintained neuronal activity and the decrease of glucose metabolism in the AD brain [12].”
BackgroundPrion-Like Propagation in Neurodegenerative Diseases
Peelaerts, W., Baekelandt, V., & Brundin, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00008-0 · Cited by 4
Medical treatment of the motor features of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C. L., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00006-8 · Cited by 5
Game changer: Navigating between challenges and hopes in geropharmacology
Chen, Q., Hartman, R., Dankiv, L., Yan, E., Young, L. H., & Barsotti, R. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.007 · Cited by 2
Cytoprotective effects of Gymnemic Acid 1 in cellular models of neurodegeneration
Kapse, S. S., & Migliore, M. M. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110673 · Cited by 2
GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
Santiago, J. A., Gutierrez-Silva, J. C., Hsu, W.-C., Sanchez, K., Almanza, C., Ramos, W., Haq, I. U., & Rundek, T. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.001 · Cited by 4
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Teil, M., & Huot, P. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103164 · Cited by 2
Raza, H., Nizam, B., Padaniya, A., Farid, M. A., Nabi, A., Hasan, M. Q., Salih, M., Patel, A. H., Inam, N., Rehman, M. E. U., et al. (2026) · Brain and Behavior · doi:10.1002/brb3.71344 · Cited by 2
Juthi, S. S., Ansari, P., Ahmed, M. F., Khan, J. T., Seidel, V., Kumar, S., Kumari, R., McKillop, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798309 · Cited by 2
Ali, M., Sharma, A., Paruchuri, A. V., Shahzad, F., Khalid, M. B., Nb, K., Avanaki, M., Nithyanandam, A., Khan, T., & Suresh, V. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08929-1 · Cited by 5
GLP-1 and Parkinson’s Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy
Mezabrovschi, R., Gegg, M. E., & Schapira, A. H. V. (2026) · Cells · doi:10.3390/cells15090804 · Cited by 3
“…emerged from a 2013 single-blind proof-of-concept trial involving 45 patients with moderate PD, in which 12 months of exenatide treatment was associated with significant improvements in the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) compared with non-use [166].”
Mourtzos, M.-A., Patoulias, D., Keklikoglou, N.-M., Karakasis, P., de Piñeres, V. G., Stefanakis, K., Rizzo, M., & Mantzoros, C. S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113345 · Cited by 3
Dahshan, A., Khalil, M. I. M., El-Jaafary, S. I., & Yamani, A. (2026) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2026.100461 · Cited by 2
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Chen, H.-C., Wang, C., Chen, H.-H., & Liou, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269006 · Cited by 2
“Exenatide, a glucagon-like peptide-1(GLP-1), is a second-line treatment for type 2 diabetes mellitus (DM) and has demonstrated clinical benefits for patients with PD in randomised controlled trials (RCT) in 2013 [10,11].”
BackgroundGill, H., Lieberman, J. M., Vincenzo, J. D. D., Rodrigues, N. B., Mansur, R. B., Mckenzie, A., Phan, L., Rosenblat, J. D., & McIntyre, R. S. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00281-3 · Cited by 2
Singh, M. P., Balasundaram, M. K., & Singh, A. (2025) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_393_2024 · Cited by 3
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Fight against Glucose Rescues Age-Related Cognitive Decline
(2016) · Neuroscience Communications · doi:10.14800/nc.862 · Cited by 2
“In 2013, a study reported that exenatide improves cognitive outcome in patients with Parkinson's disease, signifying the first steps of the GLP-1 receptor agonist into the clinic use in neuroprotection ([57]).”
BackgroundYarnall, A. J. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.7 · Cited by 2
Troshneva, A. Y., & As, A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212211212 · Cited by 3
Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Omidi, S., Mehrpouya, M., Oladnabi, M., Azadmehr, A., Kazemi‐Lomedasht, F., & Yardehnavi, N. (2021) · Venoms and Toxins · doi:10.2174/2666121701666211124151529 · Cited by 2
Parkinson’s Disease, Diabetes and Cognitive Impairment
Politis, M., Ashraghi, M. R., Pagano, G., Polychronis, S., & Niccolini, F. (2016) · Recent Patents on Endocrine Metabolic & Immune Drug Discovery · doi:10.2174/1872214810666160630191119 · Cited by 5
GLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
Diabetes mellitus and neurodegenerative disorders
Amin, S. N., Albakri, K. A., Alabdallat, Y. J., & Elberry, D. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00009-9 · Cited by 1
Uhrenholt, N. G., Ganeshalingam, A. A., Arnfred, S., Gæde, P., Pedersen, A. K., Larsen, P. V., Frystyk, J., & Bilenberg, N. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.02.009 · Cited by 4
Yelleswarapu, N. K., & Sidiropoulos, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062560 · Cited by 1
Levodopa Efficacy and GLP ‐1 Receptor Agonists
Martinez, C., Girges, C., Foltynie, T., & Wills, A.-M. A. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70591 · Cited by 1
Self-citationThe neuro-metabolic epidemic and the CB1R paradox
Vaccaro, F., Malta, G., Rizzo, M., Plescia, F., & Lavanco, G. (2026) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2026.102631 · Cited by 1
Elghanam, Y., & Kim, E. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01615-y · Cited by 3
“Most trials were double-blind, except for an open-label MCI trial (Dei Cas et al. 2024) and a single-rater blinded PD proof-of-concept trial (Aviles-Olmos et al. 2013).”
InfluentialGlucagon-like peptide-1 agonists in Parkinson’s disease: a meta-analysis
Abdallah, A. K., Harb, A., Mansour, A., Nasreldin, A., Hamdy, R., Hatem, N., Mosad, N., Hamouda, M., Hamouda, A., & Arumaithurai, K. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09238-3 · Cited by 2
Savica, R., & Bloem, B. R. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108951 · Cited by 1
REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION
Parmar, M., & Panchal, S. S. (2019) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.0912297 · Cited by 1
Wyse, R. K. H., Cooper, A. A., & Stott, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00024 · Cited by 1
Self-citationEficácia terapêutica do exenatide no tratamento da doença de Parkinson: revisão sistemática
Alcântara, A. L. D. L. N., Cardoso, A. L. F. B., Pereira, M. I. P., de Aquino, D. S. A., & Mayer, A. B. (2023) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v22i2.52661 · Cited by 2
Troshneva, A. Y., & As, A. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01488-4 · Cited by 1
“An open clinical trial showed a signi fi cant reduction in the motor and cognitive manifestations of PD [93].”
BackgroundCan venoms be used in neuroprotection?
Gazerani, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23763-8.00003-8 · Cited by 1
Disease-modifying therapy trials in PD: what are the issues?
Evans, J. (2014) · Advances in Clinical Neuroscience & Rehabilitation · doi:10.47795/dhzf6861 · Cited by 1
Cellular Adaptations to Intermittent Fasting with Emphasis on the Brain
Mattson, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-49622-6_7 · Cited by 2
Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
Dhaneshwar, S. S., Bhat, M. A., Singh, A., & Roy, S. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010012 · Cited by 2
Revisiting Parkinson’s Disease Treatment: Exploring Established Medications and Emerging Therapies
Brooks, D., Carter, A., Moore, E., & Grant, O. (2024) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/i340840675 · Cited by 1
Zhao, J., Imai, R., Ukon, N., Shimoyama, S., Tan, C., Maejima, Y., Omiya, Y., Takahashi, K., Nan, G., Zhao, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.657663 · Cited by 1
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Menon, S., Handley, J. D., & Emsley, H. C. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990 · Cited by 1
Avaliação da ação antiparkinsoniana do peptídeo Neurovespina no modelo murino da Doença de Parkinson
Campos, G. A. A. (2016) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2016.02.d.19867 · Cited by 4
Diabetes drug slows development of Parkinson’s disease
Adam, D. (2024) · Nature · doi:10.1038/d41586-024-00974-0 · Cited by 1
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Exenatide provides benefit in Parkinson's disease
Charlotte, H. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4060
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimer’s disease
Femminella, G. D., & Edison, P. (2014) · Clinical Investigation · doi:10.4155/cli.14.12
Blinding in randomized control trials: the enigma unraveled.
Saxena, V., Naithani, M., & Mirza, A. A. (2016) · Indian Journal of Community Health
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014)
Glucagon-Like Peptide 1, Neuroprotection and Neurodegenerative Disorders
Fedele, E. (2016) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000e151
“In the first case, a single-blind proof of concept evaluated the progression of motor and nonmotor symptoms in a small group of PD patients treated with exenatide (exendin-4) administered subcutaneously for 12 months and found clinically relevant ameliorations both in motor and cognitive performances, evaluated by MDS…”
MethodCentral Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and
McGrath, N., Glastras, S. J., HOCKING, S. L., Tjoeng, I., Krause, M., Fulcher, G. R., & McGrath, R. T. (2015)
Controlled Delivery of Therapeutic Proteins to the Injured Spinal Cord
Donaghue, I. E. (2016) · TSpace (University of Toronto)
姫野, 龍., 英紀, 神., & 中村, 二. (2017) · 糖尿病 · doi:10.11213/tonyobyo.60.579
High priority publications on Parkinson's disease in 2017
Simuni, T., & Krainc, D. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30416-7
Update Pharmakotherapie bei Parkinson
Ceballos-Baumann, A., & Fietzek, U. M. (2018) · Nervenheilkunde · doi:10.1055/s-0038-1641240
“Danach verschlechtern sich die beiden Behandlungsgruppen mit einer ähnlichen Dynamik (53).”
BackgroundNeuroinflammation modifying approaches in Parkinsons disease
Samur, D. N., & Özbey, G. (2018) · The Journal of Neurobehavioral Sciences · doi:10.5455/jnbs.1517915407
Pan-organ model integration of metabolic and regulatory processes in type 1 diabetesPreprint
Guebila, M. B., & Thiele, I. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/859876
“Furthermore, a clinical trial has repurposed Exenatide, a glucagon-like peptide-1 (GLP-1), in the treatment of PD (Athauda et al., 2017; Aviles-Olmos et al., 2013; Aviles-Olmos et al., 2014).”
BackgroundPick the Company 企業紹介(第76回 2)株式会社TV・ポータル
平田, 和., & 武居, 邦. (2010) · 衛星&ケーブルテレビ
Storey, S. (2013) · British Journal of Neuroscience Nursing · doi:10.12968/bjnn.2013.9.4.204
Poewe, W. H., & Mahlknecht, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727879031.793537429
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.